Z Gastroenterol 2024; 62(09): 1574-1643 Getting into treatment guidelines is lengthy, especially for new products that need time to gather sufficient scientific and real-life evidence. For this reason, we are glad to announce that Noventure´s mucoprotectants gelatin tannate and xyloglucan have been mentioned on good terms in the new guideline [...]
Olive tree (Olea europaea) leaf extract (OELE) has important antioxidant and anti-inflammatory properties, supporting its use in human clinical practice (1). A clinical trial and a sub-analysis of it conducted with the amorphous hydrogel EHO-85, containing OELE, for skin ulcer treatments were recently published (2-3). In a new publication, the [...]
The excess of free radicals in the wound environment contributes to its stagnation during the inflammatory phase, favouring hard-to-heal wounds. Oxidative stress negatively affects cells and the extracellular matrix, hindering the healing process. In this study the investigators evaluated the antioxidant and wound-healing properties of a novel multifunctional amorphous hydrogel-containing Olea [...]
We would like to announce our new partnership with Devicare, S.L., to bring Utipro Plus AF into the Spanish market! We’re excited about this new alliance and grateful for the trust placed in us. Interested in exploring business opportunities with us? Contact us! https://noventure.com/contact-us [...]
Last July 2024, information from the Journal of Wound Management, the official journal of the European Society of Wound Management (EWMA), was published on Linkedin. It contains the results of a study carried out with the EHO-85 hydrogel in anal fissures. At Noventure, we are very pleased to note that [...]
Chronic wounds, especially those that are hard-to-heal, constitute a serious public-health problem. To evaluate the superiority of a hydrogel (EHO-85), containing Olea europaea leaf extract over a standard hydrogel the promotion and/or improvement of healing of difficult-to-heal wounds was compared in a prospective, parallel-group multicenter, randomized, observer-blinded, controlled trial. Non-hospitalized [...]
GREAT NEWS! Noventure is delighted to announce that our medical device Tasectan has just been granted a new CЄ Certificate under MDR Regulation. With 3,7 Mio packs, equivalent to more than 51 Mio of standard units sold through our licensees in 34 countries during 2023, the Tasectan franchise is already [...]
We are happy to inform that Utipro® Plus AF is ready to land in Central Asia thanks to its very recent registration in Kazakhstan. All evidence supporting the product has been evaluated by the Kazakh Ministry of Health who validated the CE certification of the product and accepted its medical [...]
We are happy to announce the publication of new evidence on the benefit of an antibiotic-free approach (xyloglucan, hibiscus and propolis for oral administration) in the management of uncomplicated urinary tract infections. The objective of this very recent publication in Uro was the evaluation of the efficacy of an oral [...]